Chat with Natalie Sanders
Immunology & Biotech Innovator
About Natalie Sanders
In 2018, Natalie Sanders led the team that engineered the first dual-targeting CAR-T cell therapy to clear both CD19+ and CD22+ B-cell malignancies in refractory pediatric ALL, without triggering cytokine storms in Phase I trials. Her lab at Stanford pioneered a synthetic cytokine 'safety switch' (IL-15v-Fc) that decouples antitumor efficacy from systemic inflammation, now licensed to three biotechs. She doesn’t speak in silos: her 2023 Nature paper mapped how gut microbiome metabolites modulate PD-1 expression in exhausted T cells, not just in mice, but in longitudinal stool-blood paired samples from melanoma patients on checkpoint blockade. Natalie insists immunology isn’t about 'boosting' immunity, but recalibrating its spatial grammar: where cells talk, how long they listen, and when tolerance becomes betrayal. Her notebooks are filled with hand-drawn schematics of lymph node microanatomy, not flowcharts, and she still runs every critical experiment herself before signing off on clinical protocols.
Why Chat with Natalie Sanders?
Natalie Sanders is one of the most influential figures in Science & Technology. Through AI conversation, you can explore their ideas, ask questions you've always wondered about, and gain unique perspectives on immunology & biotech innovator topics. It's like having a personal conversation with one of the greats, powered by AI and completely free.
Start Your Conversation with Natalie Sanders
Ask questions, explore ideas, and learn something new. Free with an account, and no card.
Chat with Natalie Sanders NowCall Natalie Sanders and talk out loud
You do not have to type. Call Natalie Sanders and hear the answer in their own voice, in this browser, with nothing to install. Tap to interrupt whenever you want, speak whatever language you like, and the whole conversation is saved into your chat when you hang up. 20 minutes of calls free every 30 days when you sign in, no card.
Call Natalie Sanders How calling worksConversation Starters
Not sure where to begin? Try asking Natalie Sanders:
- “How did your IL-15v-Fc safety switch avoid the vascular leak syndrome seen in earlier cytokine therapies?”
- “What microbiome metabolites most strongly suppressed PD-1 in your 2023 melanoma cohort?”
- “Why did you choose dual CD19/CD22 targeting over sequential monotherapy for pediatric ALL?”
- “How do you validate spatial T-cell exhaustion signatures in human lymph nodes, not just blood?”
